1
|
Sonoda-Fukuda E, Takeuchi Y, Ogawa N, Noguchi S, Takarada T, Kasahara N, Kubo S. Targeted Suicide Gene Therapy with Retroviral Replicating Vectors for Experimental Canine Cancers. Int J Mol Sci 2024; 25:2657. [PMID: 38473904 DOI: 10.3390/ijms25052657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 02/17/2024] [Accepted: 02/22/2024] [Indexed: 03/14/2024] Open
Abstract
Cancer in dogs has increased in recent years and is a leading cause of death. We have developed a retroviral replicating vector (RRV) that specifically targets cancer cells for infection and replication. RRV carrying a suicide gene induced synchronized killing of cancer cells when administered with a prodrug after infection. In this study, we evaluated two distinct RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV) in canine tumor models both in vitro and in vivo. Despite low infection rates in normal canine cells, both RRVs efficiently infected and replicated within all the canine tumor cells tested. The efficient intratumoral spread of the RRVs after their intratumoral injection was also demonstrated in nude mouse models of subcutaneous canine tumor xenografts. When both RRVs encoded a yeast cytosine deaminase suicide gene, which converts the prodrug 5-fluorocytosine (5-FC) to the active drug 5-fluorouracil, they caused tumor-cell-specific 5-FC-induced killing of the canine tumor cells in vitro. Furthermore, in the AZACF- and AZACH-cell subcutaneous tumor xenograft models, both RRVs exerted significant antitumor effects. These results suggest that RRV-mediated suicide gene therapy is a novel therapeutic approach to canine cancers.
Collapse
Affiliation(s)
- Emiko Sonoda-Fukuda
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
| | - Yuya Takeuchi
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
- Departments of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Sanda 669-1330, Japan
| | - Nao Ogawa
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
- Departments of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Sanda 669-1330, Japan
| | - Shunsuke Noguchi
- Laboratory of Veterinary Radiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano 598-8531, Japan
| | - Toru Takarada
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
- Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, Kobe 658-8558, Japan
| | - Noriyuki Kasahara
- Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, CA 94143, USA
| | - Shuji Kubo
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
| |
Collapse
|
2
|
Isoda L, Sonoda-Fukuda E, Fujino H, Takarada T, Hasegawa K, Kasahara N, Kubo S. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer. Anticancer Res 2023; 43:5311-5317. [PMID: 38030176 DOI: 10.21873/anticanres.16734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 11/13/2023] [Accepted: 11/14/2023] [Indexed: 12/01/2023]
Abstract
BACKGROUND/AIM Retroviral replicating vectors (RRV) have exhibited efficient tumor transduction and improved therapeutic benefits in a variety of cancer models. In this study, we validated two RRV created from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which use different cell receptors for virus entry, in human ovarian cancer (OC) cells. MATERIALS AND METHODS Expression levels of the receptors for AMLV (PiT-2) and GALV (PiT-1) in human OC cell lines (A2780, Caov3, RMG-1, SKOV-3), fibroblasts and HEK293 cells were evaluated using quantitative RT-PCR. In vitro RRV-GFP replication was monitored using flow cytometry, and cytotoxicity quantitated using AlamarBlue assay after 5-fluorocytosine treatment of OC cells transduced with RRV expressing the yeast cytosine deaminase prodrug activator gene. In vivo antitumor effect of RRV-mediated prodrug activator gene therapy was investigated in a SKOV-3 subcutaneous tumor model. RESULTS Quantitative RT-PCR analysis revealed high expression levels of PiT-2 (AMLV receptor) and PiT-1 (GALV receptor) in the RMG-1 and SKOV3 OC cell lines, compared with their levels in non-malignant cells. In RMG-1 and SKOV3 cells, both RRV showed highly efficient RRV replication and spread leading to over 90% transduction by Days 10-13. Additionally, both RRV that express the yeast cytosine deaminase gene demonstrated effective cell killing of RMG-1 and SKOV-3 cells upon treatment with the prodrug 5-fluorocytosine. Notably, RRV-mediated prodrug activator gene therapy showed significant inhibition of subcutaneous SKOV-3 tumor growth in nude mice. CONCLUSION RRV-mediated prodrug activator gene therapy may be used for treating PiT-expressing human OC.
Collapse
Affiliation(s)
- Lisa Isoda
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan
- Department of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Sanda, Japan
| | - Emiko Sonoda-Fukuda
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan
| | - Hiroaki Fujino
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan
- Department of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Sanda, Japan
| | - Toru Takarada
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan
- Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, Kobe, Japan
| | - Kosei Hasegawa
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
| | - Noriyuki Kasahara
- Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, CA, U.S.A
| | - Shuji Kubo
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan;
| |
Collapse
|
3
|
Fujino H, Sonoda-Fukuda E, Isoda L, Kawabe A, Takarada T, Kasahara N, Kubo S. Retroviral Replicating Vectors Mediated Prodrug Activator Gene Therapy in a Gastric Cancer Model. Int J Mol Sci 2023; 24:14823. [PMID: 37834271 PMCID: PMC10573151 DOI: 10.3390/ijms241914823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 09/29/2023] [Accepted: 09/29/2023] [Indexed: 10/15/2023] Open
Abstract
Retroviral replicating vectors (RRVs) selectively replicate and can specifically introduce prodrug-activating genes into tumor cells, whereby subsequent prodrug administration induces the death of the infected tumor cells. We assessed the ability of two distinct RRVs generated from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which infect cells via type-III sodium-dependent phosphate transporters, PiT-2 and PiT-1, respectively, to infect human gastric cancer (GC) cells. A quantitative RT-PCR showed that all tested GC cell lines had higher expression levels of PiT-2 than PiT-1. Accordingly, AMLV, encoding a green fluorescent protein gene, infected and replicated more efficiently than GALV in most GC cell lines, whereas both RRVs had a low infection rate in human fibroblasts. RRV encoding a cytosine deaminase prodrug activator gene, which converts the prodrug 5-flucytosine (5-FC) to the active drug 5-fluorouracil, showed that AMLV promoted superior 5-FC-induced cytotoxicity compared with GALV, which correlated with the viral receptor expression level and viral spread. In MKN-74 subcutaneous xenograft models, AMLV had significant antitumor effects compared with GALV. Furthermore, in the MKN-74 recurrent tumor model in which 5-FC was discontinued, the resumption of 5-FC administration reduced the tumor volume. Thus, RRV-mediated prodrug activator gene therapy might be beneficial for treating human GC.
Collapse
Affiliation(s)
- Hiroaki Fujino
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan (L.I.); (T.T.)
- Departments of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Hyogo 669-1330, Japan
| | - Emiko Sonoda-Fukuda
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan (L.I.); (T.T.)
| | - Lisa Isoda
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan (L.I.); (T.T.)
- Departments of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Hyogo 669-1330, Japan
| | - Ayane Kawabe
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan (L.I.); (T.T.)
- Departments of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Hyogo 669-1330, Japan
| | - Toru Takarada
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan (L.I.); (T.T.)
- Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, Hyogo 658-8558, Japan
| | - Noriyuki Kasahara
- Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, CA 94143, USA;
| | - Shuji Kubo
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan (L.I.); (T.T.)
| |
Collapse
|
4
|
Hirano Y, Nakagomi T, Nakano-Doi A, Kubo S, Minato Y, Sawano T, Sakagami M, Tsuzuki K. Microglia Negatively Regulate the Proliferation and Neuronal Differentiation of Neural Stem/Progenitor Cells Isolated from Poststroke Mouse Brains. Cells 2023; 12:2040. [PMID: 37626850 PMCID: PMC10453473 DOI: 10.3390/cells12162040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 07/25/2023] [Accepted: 08/04/2023] [Indexed: 08/27/2023] Open
Abstract
We previously demonstrated that neural stem/progenitor cells (NSPCs) were induced within and around the ischemic areas in a mouse model of ischemic stroke. These injury/ischemia-induced NSPCs (iNSPCs) differentiated to electrophysiologically functional neurons in vitro, indicating the presence of a self-repair system following injury. However, during the healing process after stroke, ischemic areas were gradually occupied by inflammatory cells, mainly microglial cells/macrophages (MGs/MΦs), and neurogenesis rarely occurred within and around the ischemic areas. Therefore, to achieve neural regeneration by utilizing endogenous iNSPCs, regulation of MGs/MΦs after an ischemic stroke might be necessary. To test this hypothesis, we used iNSPCs isolated from the ischemic areas after a stroke in our mouse model to investigate the role of MGs/MΦs in iNSPC regulation. In coculture experiments, we show that the presence of MGs/MΦs significantly reduces not only the proliferation but also the differentiation of iNSPCs toward neuronal cells, thereby preventing neurogenesis. These effects, however, are mitigated by MG/MΦ depletion using clodronate encapsulated in liposomes. Additionally, gene ontology analysis reveals that proliferation and neuronal differentiation are negatively regulated in iNSPCs cocultured with MGs/MΦs. These results indicate that MGs/MΦs negatively impact neurogenesis via iNSPCs, suggesting that the regulation of MGs/MΦs is essential to achieve iNSPC-based neural regeneration following an ischemic stroke.
Collapse
Affiliation(s)
- Yoshinobu Hirano
- Department of Otorhinolaryngology—Head & Neck Surgery, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Japan; (Y.H.); (M.S.); (K.T.)
| | - Takayuki Nakagomi
- Institute for Advanced Medical Sciences, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan; (A.N.-D.); (S.K.)
- Department of Therapeutic Progress in Brain Diseases, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan
| | - Akiko Nakano-Doi
- Institute for Advanced Medical Sciences, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan; (A.N.-D.); (S.K.)
- Department of Therapeutic Progress in Brain Diseases, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan
| | - Shuji Kubo
- Institute for Advanced Medical Sciences, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan; (A.N.-D.); (S.K.)
| | - Yusuke Minato
- Department of Anatomy and Cell Biology, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan;
| | - Toshinori Sawano
- Department of Biomedical Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu 525-8577, Japan;
| | - Masafumi Sakagami
- Department of Otorhinolaryngology—Head & Neck Surgery, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Japan; (Y.H.); (M.S.); (K.T.)
| | - Kenzo Tsuzuki
- Department of Otorhinolaryngology—Head & Neck Surgery, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Japan; (Y.H.); (M.S.); (K.T.)
| |
Collapse
|
5
|
Nakagomi T, Nakano-Doi A, Kubo S, Sawano T, Kuramoto Y, Yamahara K, Matsuyama T, Takagi T, Doe N, Yoshimura S. Transplantation of Human Brain-Derived Ischemia-Induced Multipotent Stem Cells Ameliorates Neurological Dysfunction in Mice After Stroke. Stem Cells Transl Med 2023:7177376. [PMID: 37221140 DOI: 10.1093/stcltm/szad031] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 04/20/2023] [Indexed: 05/25/2023] Open
Abstract
We recently demonstrated that injury/ischemia-induced multipotent stem cells (iSCs) develop within post-stroke human brains. Because iSCs are stem cells induced under pathological conditions, such as ischemic stroke, the use of human brain-derived iSCs (h-iSCs) may represent a novel therapy for stroke patients. We performed a preclinical study by transplanting h-iSCs transcranially into post-stroke mouse brains 6 weeks after middle cerebral artery occlusion (MCAO). Compared with PBS-treated controls, h-iSC transplantation significantly improved neurological function. To identify the underlying mechanism, green fluorescent protein (GFP)-labeled h-iSCs were transplanted into post-stroke mouse brains. Immunohistochemistry revealed that GFP+ h-iSCs survived around the ischemic areas and some differentiated into mature neuronal cells. To determine the effect on endogenous neural stem/progenitor cells (NSPCs) by h-iSC transplantation, mCherry-labeled h-iSCs were administered to Nestin-GFP transgenic mice which were subjected to MCAO. As a result, many GFP+ NSPCs were observed around the injured sites compared with controls, indicating that mCherry+ h-iSCs activate GFP+ endogenous NSPCs. In support of these findings, coculture studies revealed that the presence of h-iSCs promotes the proliferation of endogenous NSPCs and increases neurogenesis. In addition, coculture experiments indicated neuronal network formation between h-iSC- and NSPC-derived neurons. These results suggest that h-iSCs exert positive effects on neural regeneration through not only neural replacement by grafted cells but also neurogenesis by activated endogenous NSPCs. Thus, h-iSCs have the potential to be a novel source of cell therapy for stroke patients.
Collapse
Affiliation(s)
- Takayuki Nakagomi
- Institute for Advanced Medical Sciences, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
- Department of Therapeutic Progress in Brain Diseases, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| | - Akiko Nakano-Doi
- Institute for Advanced Medical Sciences, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
- Department of Therapeutic Progress in Brain Diseases, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| | - Shuji Kubo
- Institute for Advanced Medical Sciences, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| | - Toshinori Sawano
- Department of Biomedical Sciences, Ritsumeikan University, Kusatsu, Japan
| | - Yoji Kuramoto
- Department of Neurosurgery, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| | - Kenichi Yamahara
- Institute for Advanced Medical Sciences, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| | - Tomohiro Matsuyama
- Department of Therapeutic Progress in Brain Diseases, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| | - Toshinori Takagi
- Department of Neurosurgery, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| | - Nobutaka Doe
- Department of Rehabilitation, Hyogo Medical University (Kobe Campus), Chuo-ku, Kobe, Hyogo, Japan
| | - Shinichi Yoshimura
- Institute for Advanced Medical Sciences, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
- Department of Neurosurgery, Hyogo Medical University (Nishinomiya Campus), Nishinomiya, Hyogo, Japan
| |
Collapse
|
6
|
Matsumoto T, Nakajima Y, Kubo S, Fukunaga M, Saito S, Hara H. Multicenter registry of the Watchman left atrial appendage closure device for patients with atrial fibrillation in Japan: The TERMINATOR registry. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Boston Scientific Japan
Background
Transcatheter left atrial appendage closure (LAAC) provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial fibrillation (AF). A meta-analysis of previous two randomized trials reported improved rates of hemorrhagic stroke, cardiovascular/unexplained death, and nonprocedural bleeding compared to warfarin (1). Recently, the next-generation LAAC device, the Watchman FLX system, became available, and showed a low incidence of adverse events and a high incidence of anatomic closure (2). This transcatheter stroke prevention has already been approved in Asian countries. However, there is little data of LAAC in Asian population.
Purpose
This study sought to assess efficacy and safety of LAAC for patients with nonvalvular AF in Asia.
Methods
The TERMINATOR (Transcatheter Modification of Left Atrial Appendage by Obliteration with Device) registry is a multicenter nonrandomized study in Japan. This enrolled patients who underwent LAAC in 23 Japanese institutions. The LAAC was indicated for patients with nonvalvular atrial fibrillation in whom oral anticoagulation is required, but who have a risk of bleeding (history of BARC type 3 bleeding or HAS-BLED score ≥3 points). Baseline patient and procedural characteristics and clinical outcomes were evaluated.
Results
A total of 729 patients were enrolled between September 2019 and November 2021. The mean age was 74.9±8.8 years and the mean CHA2DS2-VASc score was 4.7±1.5. The Watchman generation 2.5 and FLX system were used in 469 (64.3%) and 260 patients (35.7%), respectively. Procedural success was achieved in 722 patients (99.0%). In-hospital adverse events were as follows; 6 tamponades (0.8%), 3 pericardial effusion (0.4%), 2 device embolization (0.3%), no stroke (0%), and no death (0%). During follow-up, device-related thrombus and all-cause death were reported in 16 (2.2%) and 23 patients (3.2%), respectively.
Conclusions
LAAC with the Watchman system provides compatible efficacy and safety outcomes in Asian population.
Collapse
Affiliation(s)
- T Matsumoto
- Shonan Kamakura General Hospital, Department of Cardiology and Catheterization Laboratories , Kamakura , Japan
| | - Y Nakajima
- Iwate University Hospital, Division of Cardiology, Department of Internal Medicine , Iwate , Japan
| | - S Kubo
- Kurashiki Central Hospital, Department of Cardiology , Kurashiki , Japan
| | - M Fukunaga
- Kokura Memorial Hospital, Department of Cardiology , Kokura , Japan
| | - S Saito
- Shonan Kamakura General Hospital, Department of Cardiology and Catheterization Laboratories , Kamakura , Japan
| | - H Hara
- Toho University Ohashi Medical Center, Division of Cardiovascular Medicine , Tokyo , Japan
| |
Collapse
|
7
|
Takagi-Kimura M, Tada A, Kijima T, Kubo S, Ohmuraya M, Yoshikawa Y. BAP1 depletion in human B-lymphoblast cells affects the production of innate immune cytokines and chemokines. Genes Cells 2022; 27:731-740. [PMID: 36300836 DOI: 10.1111/gtc.12988] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 09/19/2022] [Accepted: 10/21/2022] [Indexed: 12/13/2022]
Abstract
BRCA1 associated protein 1 (BAP1) is a ubiquitin C-terminal hydrolase that deubiquitinates histone H2AK119ub and other proteins and regulates the expression of multiple genes. The knockout of this tumor suppressor gene results in severe thymic atrophy, complete loss of the T cell lineage, and abnormal B cell development in mice. In the current study, we investigated in vitro effects of BAP1 knockout on cytokine and chemokine production using the human B-lymphoblast cell line TSCE5. We confirmed that knockout changed the production of innate immune-associated genes and their receptors. The CCL19, CCR7, CCL2, and CXCR5 genes associated with T and B cell migration were upregulated. Knockout cells producing high levels of CCL19 showed acceleration of actin polymerization, which is essential for cell migration. CD69, PTPRC, and TLR3 genes that activate inflammation were downregulated. The tumor necrosis factor ligand genes TNF, LTA, and TNFSF10 were downregulated by knockout. In knockout cells, TNFα production was strongly downregulated upon the addition of H2 O2 , but NF-κB in the basal condition and when TNFα was added was augmented, suggesting that these cells could respond to TNFα. These results indicated that BAP1 affects the expression of chemokines and cytokines, T and B cell migration, and activated inflammation associating with innate immunity.
Collapse
Affiliation(s)
- Misato Takagi-Kimura
- Department of Genetics, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
| | - Akio Tada
- Department of Respiratory Medicine, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
| | - Takashi Kijima
- Department of Respiratory Medicine, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
| | - Shuji Kubo
- Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
| | - Masaki Ohmuraya
- Department of Genetics, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
| | - Yoshie Yoshikawa
- Department of Genetics, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
| |
Collapse
|
8
|
Yamamoto M, Kubo S, Hirama N, Teranishi S, Tashiro K, Seki K, Maeda C, Hiro S, Kajita Y, Sugimoto C, Segawa W, Nagayama H, Nagaoka S, Kudo M, Kaneko T. 1089P Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Tan D, Kim Y, Lim MC, Sho M, Lu CH, Nagao S, Kubo S, Kim BG, Chen LT, Kanai M, Wang PH, Rha S, Ramar R, Wong M, Sasaki T. 101P Real-world prevalence of MSI-H/dMMR across 6 different tumor types in Asia. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Nakamoto S, Taira N, Kawada K, Takabatake D, Miyoshi Y, Kubo S, Suzuki Y, Yamamoto M, Ogasawara Y, Yoshitomi S, Hara K, Shien T, Iwamoto T, Ohsumi S, Ikeda M, Mizota Y, Yamamoto S, Doihara H. 176P The effectiveness of long-term physical activity after exercise and educational programs on breast cancer-related lymphoedema: Secondary analyses from a randomized controlled trial: The Setouchi Breast Project 10. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
11
|
Petty A, Glass LJ, Rothmond DA, Purves-Tyson T, Sweeney A, Kondo Y, Kubo S, Matsumoto M, Weickert CS. Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia. J Neuroinflammation 2022; 19:188. [PMID: 35841099 PMCID: PMC9287858 DOI: 10.1186/s12974-022-02541-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 06/22/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND There is growing evidence that neuroinflammation may contribute to schizophrenia neuropathology. Elevated pro-inflammatory cytokines are evident in the midbrain from schizophrenia subjects, findings that are driven by a subgroup of patients, characterised as a "high inflammation" biotype. Cytokines trigger the release of antibodies, of which immunoglobulin G (IgG) is the most common. The level and function of IgG is regulated by its transporter (FcGRT) and by pro-inflammatory IgG receptors (including FcGR3A) in balance with the anti-inflammatory IgG receptor FcGR2B. Testing whether abnormalities in IgG activity contribute to the neuroinflammatory abnormalities schizophrenia patients, particularly those with elevated cytokines, may help identify novel treatment targets. METHODS Post-mortem midbrain tissue from healthy controls and schizophrenia cases (n = 58 total) was used to determine the localisation and abundance of IgG and IgG transporters and receptors in the midbrain of healthy controls and schizophrenia patients. Protein levels of IgG and FcGRT were quantified using western blot, and gene transcript levels of FcGRT, FcGR3A and FcGR2B were assessed using qPCR. The distribution of IgG in the midbrain was assessed using immunohistochemistry and immunofluorescence. Results were compared between diagnostic (schizophrenia vs control) and inflammatory (high vs low inflammation) groups. RESULTS We found that IgG and FcGRT protein abundance (relative to β-actin) was unchanged in people with schizophrenia compared with controls irrespective of inflammatory subtype. In contrast, FcGRT and FcGR3A mRNA levels were elevated in the midbrain from "high inflammation" schizophrenia cases (FcGRT; p = 0.02, FcGR3A; p < 0.0001) in comparison to low-inflammation patients and healthy controls, while FcGR2B mRNA levels were unchanged. IgG immunoreactivity was evident in the midbrain, and approximately 24% of all individuals (control subjects and schizophrenia cases) showed diffusion of IgG from blood vessels into the brain. However, the intensity and distribution of IgG was comparable across schizophrenia cases and control subjects. CONCLUSION These findings suggest that an increase in the pro-inflammatory Fcγ receptor FcGR3A, rather than an overall increase in IgG levels, contribute to midbrain neuroinflammation in schizophrenia patients. However, more precise information about IgG-Fcγ receptor interactions is needed to determine their potential role in schizophrenia neuropathology.
Collapse
Affiliation(s)
- A Petty
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia
| | - L J Glass
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- Centre for Immunology and Allergy Research, Westmead Institute of Medical Research, The University of Sydney, Sydney, Australia
| | - D A Rothmond
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
| | - T Purves-Tyson
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia
| | - A Sweeney
- NSW Brain Tissue Resource Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Y Kondo
- Astellas Research Institute of America LLC, San Diego, CA, 92121, USA
| | - S Kubo
- Astellas Pharma Inc., Tsukuba, Ibaraki, 305-8585, Japan
| | - M Matsumoto
- Astellas Research Institute of America LLC, San Diego, CA, 92121, USA
| | - C Shannon Weickert
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia.
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia.
- Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, NY, 13210, USA.
| |
Collapse
|
12
|
Tanaka S, Iida H, Ueno M, Hirokawa F, Yoshida H, Ishii H, Nomi T, Nakai T, Kaibori M, Ikoma H, Noda T, Shinkawa H, Maehira H, Hayami S, Komeda K, Kubo S. Postoperative loss of independence 1 year after liver resection: prospective multicentre study. Br J Surg 2022; 109:e54-e55. [PMID: 35041737 DOI: 10.1093/bjs/znab452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 12/08/2021] [Indexed: 11/14/2022]
Affiliation(s)
- S Tanaka
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Iida
- Division of Gastrointestinal, Breast, and General Surgery, Department of Surgery, Shiga University of Medical Science, Otsu, Japan
| | - M Ueno
- Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
| | - F Hirokawa
- Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Osaka, Japan
| | - H Yoshida
- Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Ishii
- Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Nomi
- Department of Surgery, Nara Medical University, Kashihara, Nara, Japan
| | - T Nakai
- Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan
| | - M Kaibori
- Department of Surgery, Hirakata Hospital, Kansai Medical University, Hirakata, Osaka, Japan
| | - H Ikoma
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Noda
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - H Shinkawa
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Maehira
- Division of Gastrointestinal, Breast, and General Surgery, Department of Surgery, Shiga University of Medical Science, Otsu, Japan
| | - S Hayami
- Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
| | - K Komeda
- Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Osaka, Japan
| | - S Kubo
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
13
|
Warmer F, Tanaka K, Xanthopoulos P, Nunami M, Nakata M, Beidler CD, Bozhenkov SA, Beurskens MNA, Brunner KJ, Ford OP, Fuchert G, Funaba H, Geiger J, Gradic D, Ida K, Igami H, Kubo S, Langenberg A, Laqua HP, Lazerson S, Morisaki T, Osakabe M, Pablant N, Pasch E, Peterson B, Satake S, Seki R, Shimozuma T, Smith HM, Stange T, Stechow AV, Sugama H, Suzuki Y, Takahashi H, Tokuzawa T, Tsujimura T, Turkin Y, Wolf RC, Yamada I, Yanai R, Yasuhara R, Yokoyama M, Yoshimura Y, Yoshinuma M, Zhang D. Impact of Magnetic Field Configuration on Heat Transport in Stellarators and Heliotrons. Phys Rev Lett 2021; 127:225001. [PMID: 34889640 DOI: 10.1103/physrevlett.127.225001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 07/30/2021] [Accepted: 09/20/2021] [Indexed: 06/13/2023]
Abstract
We assess the magnetic field configuration in modern fusion devices by comparing experiments with the same heating power, between a stellarator and a heliotron. The key role of turbulence is evident in the optimized stellarator, while neoclassical processes largely determine the transport in the heliotron device. Gyrokinetic simulations elucidate the underlying mechanisms promoting stronger ion scale turbulence in the stellarator. Similar plasma performances in these experiments suggests that neoclassical and turbulent transport should both be optimized in next step reactor designs.
Collapse
Affiliation(s)
- Felix Warmer
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K Tanaka
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- Kyushu University, Interdisciplinary Graduate School of Engineering Sciences, Plasma and Quantum Science and Engineering, Kasuga, Fukuoka 816-8580, Japan
| | - P Xanthopoulos
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - M Nunami
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
- Nagoya University, Graduate School of Science, Nagoya 464-8603, Japan
| | - M Nakata
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - C D Beidler
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - S A Bozhenkov
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - M N A Beurskens
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K J Brunner
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - O P Ford
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - G Fuchert
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H Funaba
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - J Geiger
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - D Gradic
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K Ida
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - H Igami
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - S Kubo
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- Nagoya University, Graduate School of Science, Nagoya 464-8603, Japan
| | - A Langenberg
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H P Laqua
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - S Lazerson
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - T Morisaki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Osakabe
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - N Pablant
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - E Pasch
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - B Peterson
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - S Satake
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - R Seki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Shimozuma
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - H M Smith
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - T Stange
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - A V Stechow
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H Sugama
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Suzuki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - H Takahashi
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Tokuzawa
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Tsujimura
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Turkin
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - R C Wolf
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - I Yamada
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - R Yanai
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - R Yasuhara
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Yokoyama
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Yoshimura
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - M Yoshinuma
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - D Zhang
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| |
Collapse
|
14
|
Takayama T, Yamazaki S, Matsuyama Y, Midorikawa Y, Shiina S, Izumi N, Hasegawa K, Kokudo N, Sakamoto M, Kubo S, Kudo M, Murakami T, Nakashima O. Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study. Br J Surg 2021; 108:412-418. [PMID: 33793713 DOI: 10.1093/bjs/znaa109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 03/31/2020] [Accepted: 11/03/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND Surgical treatment for hepatocellular carcinoma (HCC) is advancing, but a robust prediction model for survival after resection is not available. The aim of this study was to propose a prognostic grading system for resection of HCC. METHODS This was a retrospective, multicentre study of patients who underwent first resection of HCC with curative intent between 2000 and 2007. Patients were divided randomly by a cross-validation method into training and validation sets. Prognostic factors were identified using a Cox proportional hazards model. The predictive model was built by decision-tree analysis to define the resection grades, and subsequently validated. RESULTS A total of 16 931 patients from 795 hospitals were included. In the training set (8465 patients), four surgical grades were classified based on prognosis: grade A1 (1236 patients, 14.6 per cent; single tumour 3 cm or smaller and anatomical R0 resection); grade A2 (3614, 42.7 per cent; single tumour larger than 3 cm, or non-anatomical R0 resection); grade B (2277, 26.9 per cent; multiple tumours, or vascular invasion, and R0 resection); and grade C (1338, 15.8 per cent; multiple tumours with vascular invasion and R0 resection, or R1 resection). Five-year survival rates were 73.9 per cent (hazard ratio (HR) 1.00), 64.7 per cent (HR 1.51, 95 per cent c.i. 1.29 to 1.78), 50.6 per cent (HR 2.53, 2.15 to 2.98), and 34.8 per cent (HR 4.60, 3.90 to 5.42) for grades A1, A2, B, and C respectively. In the validation set (8466 patients), the grades had equivalent reproducibility for both overall and recurrence-free survival (all P < 0.001). CONCLUSION This grade is used to predict prognosis of patients undergoing resection of HCC.
Collapse
Affiliation(s)
- T Takayama
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
| | - S Yamazaki
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
| | - Y Matsuyama
- Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan
| | - Y Midorikawa
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
| | - S Shiina
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
| | - N Izumi
- Department of Gastroenterology, Musashino Red Cross Hospital, Tokyo, Japan
| | - K Hasegawa
- Department of Hepato-biliary-pancreatic Surgery, School of Medicine, University of Tokyo, Tokyo, Japan
| | - N Kokudo
- Department of Hepato-biliary-pancreatic Surgery, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Sakamoto
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - S Kubo
- Department of Hepato-biliary-pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan
| | - T Murakami
- Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - O Nakashima
- Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan
| | | |
Collapse
|
15
|
Yamano T, Kubo S, Sonoda E, Kominato T, Kimura K, Yasuhara M, Kataoka K, Son J, Babaya A, Takenaka Y, Matsubara T, Beppu N, Ikeda M. Assessment of circulating microRNA specific for patients with familial adenomatous polyposis. PLoS One 2021; 16:e0250072. [PMID: 33945535 PMCID: PMC8096076 DOI: 10.1371/journal.pone.0250072] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 03/30/2021] [Indexed: 12/17/2022] Open
Abstract
Circulating microRNAs (miRNAs) are considered promising biomarkers for diagnosis, prognosis, and treatment efficacy of diseases. However, usefulness of circulating miRNAs as biomarkers for hereditary gastrointestinal diseases have not been confirmed yet. We explored circulating miRNAs specific for patients with familial adenomatous polyposis (FAP) as a representative hereditary gastrointestinal disease. Next-generation sequencing (NGS) indicated that plasma miR-143-3p, miR-183-5p, and miR-885-5p were candidate biomarkers for five FAP patients compared to three healthy donors due to moderate copy number and significant difference. MiR-16-5p was considered as an internal control due to minimum difference in expression across FAP patients and healthy donors. Validation studies by real-time PCR showed that mean ratios of maximum expression and minimum expression were 2.2 for miR-143-3p/miR-16-5p, 3.4 for miR-143-3p/miR-103a-3p, 5.1 for miR-183-5p/miR-16-5p, and 4.9 for miR-885-5p/miR-16-5p by using the samples collected at different time points of eight FAP patients. MiR-143-3p/16-5p was further assessed using specimens from 16 FAP patients and 7 healthy donors. MiR-143-3p was upregulated in FAP patients compared to healthy donors (P = 0.04), but not significantly influenced by clinicopathological features. However, miR-143-3p expression in colonic tumors was rare for upregulation, although there was a significant difference by existence of desmoid tumors. MiR-143-3p transfection significantly inhibited colorectal cancer cell proliferation compared to control microRNA transfection. Our data suggested regulation of miR-143-3p expression differed by samples (plasma or colonic tumors) in most FAP patients. Upregulation of plasma miR-143-3p expression may be helpful for diagnosis of FAP, although suppressive effect on tumorigenesis seemed insufficient in FAP patients.
Collapse
Affiliation(s)
- Tomoki Yamano
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
- * E-mail:
| | - Shuji Kubo
- Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Hyogo, Japan
| | - Emiko Sonoda
- Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Hyogo, Japan
| | - Tomoko Kominato
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Kei Kimura
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Michiko Yasuhara
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Kozo Kataoka
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Jihyung Son
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Akihito Babaya
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Yuya Takenaka
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Takaaki Matsubara
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Naohito Beppu
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Masataka Ikeda
- Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
| |
Collapse
|
16
|
Tokuzawa T, Tanaka K, Tsujimura T, Kubo S, Emoto M, Inagaki S, Ida K, Yoshinuma M, Watanabe KY, Tsuchiya H, Ejiri A, Saito T, Yamamoto K. W-band millimeter-wave back-scattering system for high wavenumber turbulence measurements in LHD. Rev Sci Instrum 2021; 92:043536. [PMID: 34243406 DOI: 10.1063/5.0043474] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 04/01/2021] [Indexed: 06/13/2023]
Abstract
A 90 GHz W-band millimeter-wave back-scattering system is designed and installed for measuring electron scale turbulence (k⊥ρs ∼ 40). A metal lens relay antenna is used for in-vessel beam focusing, and a beam diameter of less than 40 mm is achieved in the plasma core region. This antenna can be steered at an angle of 159° ± 6°, which almost covers the plasma radius. The estimated size of the scattering volume is ∼105 mm at the edge and 135 mm at the core, respectively. A 60 m corrugated waveguide is used to achieve a low transmission loss of ∼8 dB. A heterodyne detection system for millimeter-wave circuits with probing power modulation can distinguish the scattered signal from background noise.
Collapse
Affiliation(s)
- T Tokuzawa
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - K Tanaka
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - T Tsujimura
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - S Kubo
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - M Emoto
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - S Inagaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - K Ida
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - M Yoshinuma
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - K Y Watanabe
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - H Tsuchiya
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - A Ejiri
- Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa 277-8561, Japan
| | - T Saito
- Research Center for Development of Far-Infrared Region, University of Fukui, Bunkyo 3-9-1, Fukui 910-8507, Japan
| | - K Yamamoto
- Research Center for Development of Far-Infrared Region, University of Fukui, Bunkyo 3-9-1, Fukui 910-8507, Japan
| |
Collapse
|
17
|
Troisi RI, Berardi G, Morise Z, Cipriani F, Ariizumi S, Sposito C, Panetta V, Simonelli I, Kim S, Goh BKP, Kubo S, Tanaka S, Takeda Y, Ettorre GM, Russolillo N, Wilson GC, Cimino M, Montalti R, Giglio MC, Igarashi K, Chan CY, Torzilli G, Cheung TT, Mazzaferro V, Kaneko H, Ferrero A, Geller DA, Han HS, Kanazawa A, Wakabayashi G, Aldrighetti L, Yamamoto M. Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study. Br J Surg 2021; 108:196-204. [PMID: 33711132 DOI: 10.1093/bjs/znaa041] [Citation(s) in RCA: 71] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 06/03/2020] [Accepted: 09/18/2020] [Indexed: 02/06/2023]
Abstract
BACKGROUND Laparoscopic liver resection for hepatocellular carcinoma (HCC) in Child-Pugh A cirrhosis has been demonstrated as beneficial. However, the role of laparoscopy in Child-Pugh B cirrhosis is undetermined. The aim of this retrospective cohort study was to compare open and laparoscopic resection for HCC with Child-Pugh B cirrhosis. METHODS Data on liver resections were gathered from 17 centres. A 1 : 1 propensity score matching was performed according to 17 predefined variables. RESULTS Of 382 available liver resections, 100 laparoscopic and 100 open resections were matched and analysed. The 90-day postoperative mortality rate was similar in open and laparoscopic groups (4.0 versus 2.0 per cent respectively; P = 0.687). Laparoscopy was associated with lower blood loss (median 110 ml versus 400 ml in the open group; P = 0.004), less morbidity (38.0 versus 51.0 per cent respectively; P = 0.041) and fewer major complications (7.0 versus 21.0 per cent; P = 0.010), and ascites was lower on postoperative days 1, 3 and 5. For laparoscopic resections, patients with portal hypertension developed more complications than those without (26 versus 12 per cent respectively; P = 0.002), and patients with a Child-Pugh B9 score had higher morbidity rates than those with B8 and B7 (7 of 8, 10 of 16 and 21 of 76 respectively; P < 0.001). Median hospital stay was 7.5 (range 2-243) days for laparoscopic liver resection and 18 (3-104) days for the open approach (P = 0.058). The 5-year overall survival rate was 47 per cent for open and 65 per cent for laparoscopic resection (P = 0.142). The 5-year disease-free survival rate was 32 and 37 per cent respectively (P = 0.742). CONCLUSION Patients without preoperative portal hypertension and Child-Pugh B7 cirrhosis may benefit most from laparoscopic liver surgery.
Collapse
Affiliation(s)
- R I Troisi
- Division of HPB, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.,Department of Human Structure and Repair, Ghent University, Ghent, Belgium
| | - G Berardi
- Division of HPB, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.,Department of Human Structure and Repair, Ghent University, Ghent, Belgium.,Centre for Advanced Treatment of Hepato-Biliary-Pancreatic Diseases, Ageo Central General Hospital, Tokyo, Japan
| | - Z Morise
- Department of Surgery, Fujita Health University Hospital, Toyoake, Japan
| | - F Cipriani
- Hepatobiliary Surgery Division, San Raffaele Hospital, Milan, Italy
| | - S Ariizumi
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | - C Sposito
- Department of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy
| | - V Panetta
- Biostatistics Department, Sapienza University of Rome, Rome, Italy
| | - I Simonelli
- Biostatistics Department, Sapienza University of Rome, Rome, Italy
| | - S Kim
- Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul,South Korea
| | - B K P Goh
- Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore
| | - S Kubo
- Department of Surgery, Osaka City University Hospital, Osaka, Japan
| | - S Tanaka
- Department of Surgery, Osaka City University Hospital, Osaka, Japan
| | - Y Takeda
- Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan
| | - G M Ettorre
- Department of General and Hepato-Biliary-Pancreatic Surgery, Liver Transplantation Service, San Camillo Forlanini Hospital, Rome, Italy
| | - N Russolillo
- Department of Surgery, Mauriziano Hospital, Turin, Italy
| | - G C Wilson
- Division of Hepatobiliary and Pancreatic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - M Cimino
- Department of General Surgery, Humanitas University and Research Hospital, IRCCS, Milan, Italy
| | - R Montalti
- Department of Public Health, Federico II University, Naples, Italy
| | - M C Giglio
- Division of HPB, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy
| | - K Igarashi
- Centre for Advanced Treatment of Hepato-Biliary-Pancreatic Diseases, Ageo Central General Hospital, Tokyo, Japan
| | - C-Y Chan
- Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore
| | - G Torzilli
- Department of General Surgery, Humanitas University and Research Hospital, IRCCS, Milan, Italy
| | - T T Cheung
- Division of Hepato-Biliary-Pancreatic and Liver Transplantation, Queen Mary Hospital, University of Hong Kong, Hong Kong, China
| | - V Mazzaferro
- Department of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy
| | - H Kaneko
- Department of Surgery, Toho University of Tokyo, Tokyo, Japan
| | - A Ferrero
- Department of Surgery, Mauriziano Hospital, Turin, Italy
| | - D A Geller
- Division of Hepatobiliary and Pancreatic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - H-S Han
- Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul,South Korea
| | - A Kanazawa
- Department of Surgery, Osaka City General Hospital, Osaka, Japan
| | - G Wakabayashi
- Centre for Advanced Treatment of Hepato-Biliary-Pancreatic Diseases, Ageo Central General Hospital, Tokyo, Japan
| | - L Aldrighetti
- Hepatobiliary Surgery Division, San Raffaele Hospital, Milan, Italy
| | - M Yamamoto
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| |
Collapse
|
18
|
Nishiura M, Shimizu T, Kobayashi S, Tokuzawa T, Ichinose K, Kubo S. Q-band high-performance notch filters at 56 and 77 GHz notches for versatile fusion plasma diagnostics. Rev Sci Instrum 2021; 92:034711. [PMID: 33820101 DOI: 10.1063/5.0041243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Accepted: 02/24/2021] [Indexed: 06/12/2023]
Abstract
A six-pole Q-band waveguide filter with a notch frequency above the Q-band has been developed for plasma diagnostics. The previous paper [Nishiura et al., J. Instrum. 10, C12014 (2015)] reported that the notch frequency exists within the standard band. In this study, the newly required notch filter extends the function, which prevents a thorny wave from being mixed into an instrument beyond the standard bandwidth of the waveguide. The mode control technique for cavities realizes a deep and sharp filter shape for Q-band notch filters with 56 and 77 GHz notches, respectively. The former filter has an attenuation more than 50 dB at 56.05 GHz and a bandwidth of 1.1 GHz at -3 dB. The latter filter has an attenuation more than 55 dB at 76.95 GHz and a bandwidth of 1.6 GHz at -3 dB. The electron cyclotron emission imaging and the electron cyclotron emission (ECE) diagnostics for the Q-band implemented a pair of the fabricated filters and demonstrated the ECE measurement successfully in the intense stray radiation from a 56 GHz gyrotron.
Collapse
Affiliation(s)
- M Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - T Shimizu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - S Kobayashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - T Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - K Ichinose
- Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - S Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| |
Collapse
|
19
|
Masumoto A, Ohya M, Murai R, Miura K, Shimada T, Amano H, Kubo S, Tada T, Tanaka H, Fuku Y, Kadota K. Early restenosis and late catch-up phenomenon after newer biodegradable- and durable-polymer drug-eluting stent implantations. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
It is yet to be known whether mechanisms underlying restenosis in newer-generation durable-polymer (DP) and biodegradable-polymer (BP) drug-eluting stents (DES) are different.
Purpose
This study aims to assess the incidences and predictors of early restenosis and late catch-up phenomenon after newer-generation durable-polymer (DP) and biodegradable-polymer (BP) DES.
Methods
Between 2010 and 2017, 13858 lesions in 6350 patients were treated with DES (4393 BP-DES, 9465 DP-DES). The early-term (within 1 year) and late-term (from 1 to 2 years) follow-up angiographies were scheduled. Late catch-up phenomenon was defined as in-stent restenosis (ISR) in lesions that evaded ISR within 1 year after stent implantation. ISR was defined as angiographic restenosis of more than 50%.
Results
The mean patient age was 71 years, and 76.7% were male. Early-term angiographies were performed in 10955 lesions (79.0%). Of those without early-term ISR, late-term angiographies were performed in 7771 lesions (56.1%). The incidences of mid-term restenosis and late catch-up phenomenon were 6.6% and 3.9%, respectively.
In the multivariate regression analyses, history of diabetes, hemodialysis and previous PCI were independent predictors of both early restenosis and late catch-up phenomenon. Also, some lesion characteristics such as chronic total occlusion, right coronary artery ostial lesion, small vessel (defined as reference diameter <2.5mm), long lesion (defined as lesion length >30mm) and treatment of ISR lesion were independent predictors of both early restenosis and late catch-up phenomenon.
Bifurcation lesion and heavily calcified lesion treated with rotablator were independent risk of early restenosis. Bypass graft lesion was an independent predictor of late catch-up phenomenon.
Early restenosis was observed less frequently in DP-DES than in BP-DES (6.3% versus 7.4%, P=0.012). On the contrary, late catch-up phenomenon was observed more frequently in DP-DES than in BP-DES (4.3% versus 2.9%, P=0.026).
Conclusions
Some lesion characteristics were independent predictors of early restenosis and late catch-up phenomenon after newer-generation DES implantation. The deployment of BP-DES resulted in more early restenosis and less late catch-up phenomenon compared to that of DP-DES.
Early Restenosis and Late Catch-Up
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - M Ohya
- Kurashiki Central Hospital, Kobe, Japan
| | - R Murai
- Kurashiki Central Hospital, Kobe, Japan
| | - K Miura
- Kurashiki Central Hospital, Kobe, Japan
| | - T Shimada
- Kurashiki Central Hospital, Kobe, Japan
| | - H Amano
- Kurashiki Central Hospital, Kobe, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kobe, Japan
| | - T Tada
- Kurashiki Central Hospital, Kobe, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kobe, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kobe, Japan
| | - K Kadota
- Kurashiki Central Hospital, Kobe, Japan
| |
Collapse
|
20
|
Hata R, Shimada T, Shima Y, Okabe K, Ohya M, Miura K, Murai R, Amano H, Kubo S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. Clinical features and prognosis of acute myocardial infarction due to coronary artery embolism. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Coronary artery embolism (CE) is one of the important causes of acute coronary syndrome (ACS). The feature of CE is that angiographic evidence of coronary artery embolism and thrombosis without atherosclerotic components. However, the prevalence of CE remains unknown because of the diffifulty to diagnose in the acute settings. A recent retrospective analysis suggested that up to 3% of ACS cases may result from CE.
Purpose
The aim of this study was to elucidate the prevalence, clinical features and long-term outcomes including all-cause and cardiac death.
Methods
We analysed the consecutive 2695 patients with first AMI performed coronary intervention between January 2004 and July 2017. CE was diagnosed by clinical histories and angiographic findings. We retrospectively evaluated the clinical and lesion characteristics and outcomes including all-cause and cardiac death.
Results
The prevalence of CE was 2.0% (n=55; CE group and n=2640; non-CE group), including 8 (15%) patients with multivessel CE. The CE group had higher average age (70.8±14.9 vs. 68.4±12.6, p<0.01), prevalence of female (54% vs. 27%, p<0.01), lower prevalence of smoking (34% vs. 62%, p<0.01). The common causes with CE were atrial fibrillation (47%), and malignant tumor (9%), and cardiomyopathy (5%), and patent foramen ovale (4%). Only 20% of patients with CE were treated with anti-coagulant therapy. The rate of distal infarction site (defined as #4, #8, #14–15) was significantly higher in CE group than non-CE group (54.0% vs. 4.9%, p<0.01). During median follow-up of 53.6 [32.6–77.3] months, CE and thromboembolism recurred in 5 patients (CE: 1 patient, stroke 4 patients). The 4-year incidence of all-cause death was significantly higher in the CE group, but cardiac death was not significantly different between the groups (28.8% vs. 14.8%, p=0.03; 12.8% vs. 5.1%, p=0.11).
Conclusion
Compared with non-CE group, the prevalence of distal infarction site was significantly higher in the CE group, and the incidence of cardiac death is not significantly different.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- R Hata
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - Y Shima
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - K Okabe
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| |
Collapse
|
21
|
Miura K, Shimada T, Ohya M, Murai R, Amano H, Kubo S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. Risk stratification based on academic research consortium high bleeding risk criteria for long-term bleeding event after everolimus-eluting stent implantation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria has been suggested as the standard definition of HBR.
Purpose
We aimed to investigate the risk stratification based on ARC-HBR Criteria for long-term bleeding event after everolimus-eluting stent implantation
Methods
The study population comprised 1193 patients treated with EES without in-hospital event between 2010 and 2011. Individual ARC-HBR criteria was retrospectively assessed. Major bleeding were defined as the occurrence of a Bleeding Academic Research Consortium type 3 or 5 bleeding event. The mean follow-up period was 2996±433 days.
Results
There were 656 patients (55.0%) in HBR-groups. Cumulative incidence of major bleeding was significantly higher in HBR-group (8.1% vs 3.4% at 4 year, and 16.2% vs 5.7% at 8 year, P<0.001). Cumulative rate of major bleeding tend to be higher as the number of ARC-HBR criteria increased (≥2 Majors: 24.3%, 1 Major: 17.0%, ≥2 Minors:11.7%, and Non-HBR: 5.7%, P<0.001).
Conclusion
ARC-HBR criteria successfully stratified the long-term bleeding risk after drug-eluting stent implantation in real-world practice.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Miura
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
22
|
Aoki T, Kubota K, Kubo S, Kudo M. Author response to: Comment on: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg 2020; 107:470. [PMID: 32129488 DOI: 10.1002/bjs.11522] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 01/09/2020] [Indexed: 12/17/2022]
Affiliation(s)
- T Aoki
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - K Kubota
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - S Kubo
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine and, Osaka, Japan
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka, Japan
| |
Collapse
|
23
|
Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Iwata S, Hanami K, Fukuyo S, Miyagawa I, Yamaguchi A, Kawabe A, Kazuyoshi S, Tanaka Y. FRI0102 SERUM TNFΑ LEVELS AT 24 HOURS AFTER FIRST ADMINISTRATION OF CERTOLIZUMAB PEGOL PREDICT EFFECTIVENESS AT WEEK 12 IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM TSUBAME STUDY (UMIN ID:0002381). Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:To increase the remission rate of rheumatoid arthritis (RA), it is necessary to determine the efficacy of the tumor necrosis factor (TNF) inhibitor as early as possible. Moreover, the response to certolizumab pegol (CZP) at 12 weeks has been reported to predict its long-term efficacy.Objectives:As part of a prospective single-center observational study (TSUBAME study), we prospectively enrolled patients to be treated with CZP in our institution to evaluate its effectiveness and safety starting at 24 hours after the first dose in clinical settings, while recording blood CZP concentrations and biomarkers over time to examine their correlation with clinical effects.Methods:One hundred patients with RA and inadequate response to MTX who received CZP were enrolled in the TSUBAME study. The changes in serum TNFα, IL-6, and CZP levels at 24 hours after first administration of CZP were measured, and the correlation between serum biomarkers and clinical response was determined.Results:At 24 hours after CZP initiation, significant improvement was observed in the disease activity (baseline and 24 h: 5.4 ± 1.3, 5.0 ± 1.3, respectively, p < 0.01), which was maintained until week 12. (baseline and 12 w: 5.4 ± 1.3, 3.3 ± 1.4, respectively, p < 0.01). Serum TNFα and IL-6 levels significantly decreased at 24 hours after first administration of CZP compared to baseline. No correlation was found between TNFα and IL-6 levels at baseline and the clinical response. According to univariate analysis, low serum TNFα and IL-6 levels and high CZP levels at 24 hours were associated with DAS28 (ESR) remission at 12 weeks. According to multivariate analysis, low serum TNFα levels at 24 hours were significantly associated with DAS28 (ESR) remission at 12 weeks (OR 0.05, 95%CI 0.01, 0.75, p = 0.03). Based on these findings, an ROC curve was created using remission according to the DAS28 (ESR) at week 12 as a dependent variable and TNFα concentration at 24 hours as an independent variable, resulting in a cut-off value of 0.76 pg/ml. From this result, the TNFα concentration at 24 hours was divided into 2 groups according to this cut-off, and the rates of remission according to the DAS28 (ESR) at week 12 were compared. In the group with TNFα concentration at 24 hours below the cut-off value, the rate of remission according to the DAS28 (ESR) at week 12 was significantly higher than in the group with TNFα concentration at 24 hours above the cut-off value (below the cut-off: above the cut-off = 56.3%: 21.6%, p < 0.001). Between the group that achieved remission according to the DAS28(ESR) and the group that did not achieve remission at week 12, there was almost no difference in the distribution of TNFα concentrations at baseline; however, the distribution of TNFα concentrations at 24 hours was lower in the group that achieved remission.Conclusion:CZP was effective where serum TNFα was strongly neutralized within 24 hours. These results suggest that low serum TNFα levels at 24 hours after first administration of CZP may predict the effectiveness of CZP. To increase the remission rate in RA, it is necessary to determine the effectiveness of the molecular targeted drugs used at an early point, in addition to how rapid the onset of action is. CZP is extremely fast-acting, and its effectiveness can be predicted as early as 24 hours after the first dose, suggesting that it may be possible to determine the effectiveness early.Acknowledgments:The authors thank Ms. M. Hirahara for providing excellent technical assistance.Disclosure of Interests:Yusuke Miyazaki Grant/research support from: Astellas Pharma Inc and UCB S.A., Kazuhisa Nakano: None declared, Shingo Nakayamada Grant/research support from: Mitsubishi-Tanabe, Takeda, Novartis and MSD, Speakers bureau: Bristol-Myers, Sanofi, Abbvie, Eisai, Eli Lilly, Chugai, Asahi-kasei and Pfizer, Satoshi Kubo: None declared, Shigeru Iwata: None declared, Kentaro Hanami: None declared, Shunsuke Fukuyo: None declared, Ippei Miyagawa: None declared, Ayako Yamaguchi: None declared, Akio Kawabe: None declared, SAITO KAZUYOSHI: None declared, Yoshiya Tanaka Grant/research support from: Asahi-kasei, Astellas, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, Pfizer, and Ono, Consultant of: Abbvie, Astellas, Bristol-Myers Squibb, Eli Lilly, Pfizer, Speakers bureau: Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, AbbVie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Sanofi, UCB, and Teijin
Collapse
|
24
|
Ii Tsujimura T, Mizuno Y, Yanai R, Tokuzawa T, Ito Y, Nishiura M, Kubo S, Shimozuma T, Yoshimura Y, Igami H, Takahashi H, Tanaka K, Yoshinuma M, Ohshima S. Real-time control of the deposition location of ECRH in the LHD. Fusion Engineering and Design 2020. [DOI: 10.1016/j.fusengdes.2020.111480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Yamano T, Kubo S, Tomita N. A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma. Cancer Med 2020; 9:3337-3343. [PMID: 32168428 PMCID: PMC7221307 DOI: 10.1002/cam4.2986] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 02/14/2020] [Accepted: 03/01/2020] [Indexed: 01/30/2023] Open
Abstract
Basic and clinical studies on small bowel adenocarcinoma (SBA) are limited due to the rare nature of this cancer. We established a patient‐derived xenograft (PDX) model from the tumor tissue of an advanced SBA patient with liver and peritoneal metastasis, and a cell line from the PDX. In the PDX model, compared to the control group, 5‐fluorouracil (5‐FU) treatment resulted in statistically significant tumor growth inhibition (TGI), while oxaliplatin (OHP) and irinotecan had no significant inhibitory effects. In combination with 5‐FU, OHP showed the highest rate of TGI. The IC50 for OHP was significantly lower than those for paclitaxel, gemcitabine, and trifluorothymidine in the PDX‐derived cell line when compared to in HT29, a colon cancer cell line. Genetic analysis of the patient tumor, PDX tumor, and the cell line demonstrated consistency in the microsatellite status and mutations in TP53, APC, HRAS, CSF1R, FGFR3, FLT3, PDGFRA, and RET genes. However, the PDX tumor alone had additional mutations, indicating that the PDX‐derived cell line may support the unstable genetic status of the PDX. Our findings confirmed the effectiveness of the combination of OHP and 5‐FU, which is a common treatment for advanced SBA and advanced colorectal cancer, in a preclinical model. This preclinical model of SBA can help in further understanding the biology of SBA.
Collapse
Affiliation(s)
- Tomoki Yamano
- Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | - Shuji Kubo
- Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan
| | - Naohiro Tomita
- Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| |
Collapse
|
26
|
Aoki T, Kubota K, Kubo S, Kudo M. Author response to: Comment on: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg 2020; 107:465. [PMID: 32129493 DOI: 10.1002/bjs.11495] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 12/06/2019] [Indexed: 11/09/2022]
Affiliation(s)
- T Aoki
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - K Kubota
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - S Kubo
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka, Japan
| |
Collapse
|
27
|
Okabe K, Ohya M, Matsushita K, Kuwayama A, Murai R, Miura K, Shimada T, Amano H, Kubo S, Habara S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. P2693Late catch-up phenomenon and late-term target lesion revascularization of two-stenting for coronary bifurcation lesions between first and second generation drug-eluting stents. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The second generation drug-eluting stent (G2-DES) has been reported as superior to the first generation drug-eluting stent (G1-DES) in mid-term outcomes. However, the late-term outcomes between G1-DES and G2-DES in two-stenting for coronary bifurcation lesions are not well studied.
Purpose
To evaluate the late catch-up phenomenon and late-term target lesion revascularization (TLR) of two-stenting for coronary bifurcation lesions between G1-DES and G2-DES.
Methods
This study included 1133 lesions in 1089 patients undergoing drug eluting stent implantation with two stenting from 2004 to 2016. These consisted of 496 G1-DES implanted lesions and 637 G2-DES implanted lesions. Late-term follow-up angiography was performed without in-stent restenosis (ISR) and TLR at mid-term follow-up in 582 lesions (242 G1-DES lesions and 340 G2-DES lesions). ISR was defined as more than 50% restenosis. Late catch-up phenomenon was defined as ISR without ISR within 1 year following index stent implantation. Late-term TLR was defined as from 1 to 5 year TLR. Bifurcation lesions were defined as the main branch ranging from the proximal stem to the distal main branch with boundaries defined by 5 mm proximal and distal to the stent-implanted area, and the side branch ranging from the bifurcation carina to the distal side branch with boundaries defined by the carina and 5 mm distal to the stent-implanted area.
Results
The median follow-up duration was 5.1 years (the first and third quarters, 3.2 and 7.1 years). The late-catch up phenomenon rate significantly differed between the G1-DES and G2-DES groups (16.9% vs 8.4%, p=0.001). A significant difference in late catch-up between the same two groups was also observed in bifurcation lesions of the main branch (5.0% vs 0.6%, p=0.001) and side branch (10.3% vs 5.6%, p=0.033), respectively. The 5-year cumulative rates also differed between the two groups in TLR (8.2% vs 3.7% log-rank p=0.001), and late-term TLR (7.0% vs 3.6% log-rank p=0.001).
Conclusion
Two-stenting using G2-DES, compared with G1-DES, significantly reduced late-term restenosis and TLR. The restenosis rate in bifurcation area may be associated with differences between two groups in late-term outcome.
Collapse
Affiliation(s)
- K Okabe
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - K Matsushita
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - A Kuwayama
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| |
Collapse
|
28
|
Tada T, Miura K, Ohya M, Shimada T, Murai R, Amano H, Kubo S, Habara S, Tanaka H, Fuku Y, Kadota K. P5614The association between tissue morphology assessed with optical coherence tomography and mid and late-term results after percutaneous coronary intervention for in-stent restenosis lesions. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
It was reported that tissue morphology of in-stent restenosis (ISR) lesions assessed with optical coherence tomography (OCT) had an effect on midterm results including ISR and target lesion revascularization (TLR) rates after percutaneous coronary intervention (PCI). However, little was known about the association between tissue morphology assessed with OCT and late-term results.
Methods
We performed PCI treated with paclitaxel coated balloon (PCB) or drug-eluting stent (DES) for 452 ISR lesions (260 lesions with fibrous plaque and 192 lesions with lipid-laden plaque) using OCT between May 2008 and July 2016. Six- to eight-month (midterm) angiographic follow-up was performed on 422 of the 452 ISR lesions (follow-up rate: 93.4%). Furthermore, eighteen- to twenty-month (late-term) angiographic follow-up was performed on 337 of the 361 ISR lesions (follow-up rate: 93.4%) which were free from midterm TLR. We examined the association between tissue morphology, midterm-results and late-term results including ISR and TLR rates. Fibrous plaque was defined as homogeneous, signal-rich regions with low attenuation. Lipid-laden plaque was defined as diffuse border, signal poor regions with high attenuation.
Results
The patients were 353 men and 69 women, and the mean age was 68.8±9.6 years. PCI were performed with PCB in 285 lesions (PCB group) and DES in 137 lesions (DES group). The figure shows the angiographic midterm results of the 422 lesions and late-term results of the 337 lesions with respect to each tissue morphology and each PCI device. There was no difference in ISR and TLR rates of lesions with both fibrous and lipid-laden plaque at midterm between the two groups. ISR and TLR rates of lesions with lipid-laden plaque at late-term were significantly higher in the PCB group than in the DES group, while there was no difference in ISR and TLR rates of lesions with fibrous plaque at late-term between two groups.
Figure 1
Conclusion
Tissue morphology of ISR lesions might have an impact on outcomes after PCI. Morphological assessment of ISR tissue using OCT might suggest favorable types of PCI for ISR lesions.
Collapse
Affiliation(s)
- T Tada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| |
Collapse
|
29
|
Idei H, Onchi T, Kariya T, Tsujimura T, Kubo S, Kobayashi S, Sakaguchi M, Imai T, Hasegawa M, Nakamura K, Mishra K, Fukuyama M, Yunoki M, Kojima S, Watanabe O, Kuroda K, Hanada K, Nagashima Y, Ejiri A, Matsumoto N, Ono M, Higashijima A, Nagata T, Shimabukoro S, Takase Y, Fukuyama A, Murakami S. 28-GHz ECHCD system with beam focusing launcher on the QUEST spherical tokamak. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.02.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Fukuyama M, Idei H, Tsujimura T, Kubo S, Kobayashi S, Yunoki M, Onchi T, Ikezoe R. Quasi-optical polarizer system for ECHCD experiments in the QUEST. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.02.099] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Nagasaki K, Watanabe S, Sakamoto K, Isayama A, Okada H, Minami T, Kado S, Kobayashi S, Yamamoto S, Ohshima S, Konoshima S, Mizuuchi T, Nakamura Y, Ishizawa A, Kubo S, Igami H, Weir G, Marushchenko N. Measurement of stray millimeter-wave radiation from a 70-GHz ECH/ECCD system in Heliotron J. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.04.051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
32
|
Yamano T, Kubo S, Yano A, Kominato T, Tanaka S, Ikeda M, Tomita N. Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy. Oncotarget 2019; 10:352-367. [PMID: 30719229 PMCID: PMC6349454 DOI: 10.18632/oncotarget.26564] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 12/29/2018] [Indexed: 12/22/2022] Open
Abstract
FR901464 (FR) was first described as an anticancer drug and later identified as a modulator of splicing factor 3B subunit 1 (SF3B1). Although the effectiveness of splicing modulators has been investigated in colorectal cancer (CRC) cells, their usefulness in animal experiments has not been confirmed. The association of SF3B1 with CRC progression and the influence of FR on transcriptional activity in CRC has not been fully elucidated. FR showed strong cytotoxicity against CRC cell lines, SF3B1-mutated cancer cell lines, and human fibroblasts with IC50 values less than 1 ng/ml. FR-resistant clones derived from HCT116, DLD1, Lovo, and CT26 cells showed IC50 values greater than 100 ng/ml. SF3B1 sequencing demonstrated low frequencies of SF3B1 mutations in CRC and mutations in codon 1074 of exon 22 in all FR-resistant clones. Unlike hematological malignancies, SF3B1 expression was not associated with CRC progression. Although FR showed significant growth inhibition in a xenograft model of RKO cells, severe toxicity was also induced. These data indicated CRC might be a suitable target of FR unless toxicity occurs. Microarray analysis and real-time quantitative PCR demonstrated downregulation of genes associated with Fanconi anemia (BRCA1 and BRCA2) and 28 driver oncogenes. These data suggested combination treatment of FR with other anticancer drugs whose sensitivity is associated with genes affected by FR treatment. Combination treatment with PARP1 inhibitor olaparib, whose sensitivity was enhanced by BRCA 1/2 deficiency, showed synergistic effects in CRC cells. Our data indicates the potential of FR in combination therapy rather than monotherapy for CRC treatment.
Collapse
Affiliation(s)
- Tomoki Yamano
- Division of Lower Gastrointestinal Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Shuji Kubo
- Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Aya Yano
- Division of Lower Gastrointestinal Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Tomoko Kominato
- Division of Lower Gastrointestinal Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Shino Tanaka
- Division of Lower Gastrointestinal Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Masataka Ikeda
- Division of Lower Gastrointestinal Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Naohiro Tomita
- Division of Lower Gastrointestinal Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| |
Collapse
|
33
|
Nishikawa T, Miyamatsu N, Higashiyama A, Hojo M, Nishida Y, Fukuda S, Ichiura K, Kubo S, Ueba T, Okamura T. Difference in water intake between persons with a history of cerebral infarction and healthy persons. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky214.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - N Miyamatsu
- Department of Clinical Nursing, Shiga University of Medical Science, Shiga, Japan
| | - A Higashiyama
- Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - M Hojo
- Department of Neurosurgery, Shiga General Hospital, Shiga, Shiga, Japan
| | - Y Nishida
- Foundation for Biomedical Research and Innovation, Hyogo, Japan
| | - S Fukuda
- Department of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | - K Ichiura
- Department of Clinical Nursing, Shiga University of Medical Science, Shiga, Japan
| | - S Kubo
- Foundation for Biomedical Research and Innovation, Hyogo, Japan
| | - T Ueba
- Department of Neurosurgery, Kochi Medical School, Kochi University, Kochi, Japan
| | - T Okamura
- Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan
| |
Collapse
|
34
|
Nomura T, Maeno Y, Abramowitz Y, Yoon S, Kubo S, Jilaihawi H, Kawamori H, Kazuno Y, Miyasaka M, Takahashi N, Kashif M, Chakravarty T, Nakamura M, Sharma R, Makkar R. P6311Prognostic impact of permanent pacemaker implantation in patients with low left ventricular ejection fraction following transcatheter aortic valve replacement. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Nomura
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - Y Maeno
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - Y Abramowitz
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - S Yoon
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - S Kubo
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - H Jilaihawi
- New York University Langone Medical Center, New York, United States of America
| | - H Kawamori
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - Y Kazuno
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - M Miyasaka
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - N Takahashi
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - M Kashif
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - T Chakravarty
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - M Nakamura
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - R Sharma
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - R Makkar
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| |
Collapse
|
35
|
Kubo S, Kadota K. P3575Procedural and angiographic outcomes of main-branch stenting with side-branch drug-coated balloon inflation strategy for bifurcation lesions. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- S Kubo
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| |
Collapse
|
36
|
Sabbah M, Kadota K, Tada T, Kubo S, Hyodo Y, Otsuru S, Habara S, Tanaka H, Fuku Y, Goto T. P752Clinical and angiographic outcomes of true versus false lumen stenting of coronary chronic total occlusions: insights from intravascular ultrasound. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Sabbah
- Suez Canal University, Department of Cardiology, Ismailia, Egypt
| | - K Kadota
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Hyodo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Otsuru
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
37
|
Amano H, Kadota K, Kuwayama A, Miura K, Ohya M, Shimada T, Kubo S, Otsuru S, Habara S, Tada T, Tanaka H, Fuku Y, Goto T. P4560Long-term outcomes of iatrogenic coronary artery dissection during cardiac catheterization. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4560] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Amano
- Kurashiki Central Hospital, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Kurashiki, Japan
| | - A Kuwayama
- Kurashiki Central Hospital, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Otsuru
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
38
|
Ohya M, Kuwayama A, Miura K, Shimada T, Murai R, Amano H, Kubo S, Otsuru S, Habara S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. P3673In-hospital bleeding and utility of a maintenance dose of prasugrel 2.5 mg in high bleeding risk patients with acute coronary syndrome. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Ohya
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - A Kuwayama
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Otsuru
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| |
Collapse
|
39
|
Kubo S, Takagi-Kimura M, Kasahara N. Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors. Cancer Gene Ther 2018; 26:41-47. [PMID: 30042500 PMCID: PMC6760559 DOI: 10.1038/s41417-018-0037-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2018] [Revised: 05/12/2018] [Accepted: 05/24/2018] [Indexed: 11/09/2022]
Abstract
Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction and enhanced therapeutic benefit in a wide variety of cancer models. Here, we evaluated two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular receptors (PiT-2 and PiT-1, respectively) for viral entry, in human osteosarcoma cells. Quantitative RT-PCR showed that low levels of expression of both receptors were observed in normal and non-malignant cells. However, high PiT-2 (for AMLV) and low PiT-1 (for GALV) expression was observed in most osteosarcoma cell lines. Accordingly, AMLV expressing the green fluorescent protein gene infected and replicated more efficiently than GALV in most osteosarcoma cell lines. Furthermore, RRVs expressing the cytosine deaminase prodrug activator gene showed differential cytotoxicity that correlated with the results of viral spread. AMLV-RRV-mediated prodrug activator gene therapy achieved significant inhibition of subcutaneous MG-63 tumor growth over GALV in nude mice. These data indicate that AMLV vectors predominate over GALV in human osteosarcoma cells. Moreover, our findings support the potential utility of the two RRVs in personalized cancer virotherapy on the basis of receptor expression.
Collapse
Affiliation(s)
- Shuji Kubo
- Unit of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan.
| | - Misato Takagi-Kimura
- Unit of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan
| | - Noriyuki Kasahara
- Departments of Cell Biology and Pathology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| |
Collapse
|
40
|
Hishikawa N, Toyama S, Ikoma K, Taniguchi D, Kido M, Ohashi S, Kubo S, Maeda H, Sawada K, Mikami Y, Toshikazu K. ISPR8-0437/The abnormalities of the hip and knee joints in patients with posterior tibialis tendon dysfunction: Comparison with healthy age-matched controls. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 2018; 27:802-811. [DOI: 10.1177/0961203317749047] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
Objective We examined the efficacy and safety of rituximab in patients with refractory systemic lupus erythematosus (SLE). Methods The study enrolled 63 SLE patients who were treated with rituximab between 2002 and 2015. The participants underwent a battery of tests before treatment and at one year. Treatment ranged from two to four times at 500 or 1000 mg. Results Baseline characteristics were males:females = 6:57, age 33.9 years, and disease duration 87.2 months. The primary endpoint: The rate of major clinical response (MCR) was 60% while the partial clinical response (PCR) was 25%. Thirty of 36 (83%) patients with lupus nephritis (WHO II: 2, III: 5, IV: 22, V: 4, IV+V: 2, not assessed: 1) and 22 of 24 patients (92%) with neuropsychiatric SLE, who could be followed at one year, showed changes from BILAG A or B score to C or D score at one year. Multivariate analysis identified high anti-dsDNA antibody and shorter disease duration as significant determinants of MCR at one year. Repeat examination was conducted at five years. Primary failure was recorded in 8.8% and secondary failure in 32.4% (time to relapse: 24.4 months). Rituximab was well tolerated although 65 adverse events, mostly infections, were recorded within one year. Conclusion Rituximab is potentially efficacious for the treatment of patients with refractory SLE.
Collapse
Affiliation(s)
- S Iwata
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - K Saito
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - S Hirata
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - N Ohkubo
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - S Nakayamada
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - K Nakano
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - K Hanami
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - S Kubo
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - I Miyagawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - M Yoshikawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - Y Miyazaki
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - H Yoshinari
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - Y Tanaka
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| |
Collapse
|
42
|
Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus 2018. [PMID: 29523055 DOI: 10.1177/0961203318762598] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
It has been reported that T helper 17 cells are involved in the pathogenesis of systemic lupus erythematosus, but there is no report on interleukin-17-targeted therapy. We report a case of a 62-year-old female who presented with psoriasis vulgaris and refractory lupus nephritis. Because her conditions were resistant to conventional treatment, and flow cytometry confirmed the proliferation of activated T helper 17 cells in peripheral blood, and examination of a renal biopsy tissue sample confirmed infiltration of numerous interleukin-17-positive lymphocytes to the renal interstitium, administration of the anti-interleukin-17A antibody secukinumab was initiated. After starting secukinumab the clinical and biological features were improved.
Collapse
Affiliation(s)
- Y Satoh
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - K Nakano
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - H Yoshinari
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - S Nakayamada
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - S Iwata
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - S Kubo
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - I Miyagawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - M Yoshikawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - Y Miyazaki
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - K Saito
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - Y Tanaka
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| |
Collapse
|
43
|
Nishikawa T, Miyamatsu N, Higashiyama A, Hojo M, Nishida Y, Fukuda S, Ichiura K, Kubo S, Okamura T. PO2-5DIFFERENCES IN DRINKING HISTORY BETWEEN HEALTHY PEOPLE AND PATIENTS WITH CEREBRAL INFARCTION. Alcohol Alcohol 2017. [DOI: 10.1093/alcalc/agx074.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Nomura E, Ohshita T, Naka H, Matsushima H, Kubo S, Takeshima S, Imamura E, Torii T, Hosomi N, Maruyama H, Matsumoto M. Stroke recurrence or death during 2 weeks after acute ischemic stroke with atrial fibrillation - multicenter prospective registry in Hiroshima –. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Godai K, Miyamatsu N, Higashiyama A, Kubo S, Nishida Y, Sugiyama D, Nii Y, Tatsumi Y, Nishikawa T, Okamura T. PO3-2ALCOHOL CONSUMPTION AND PSYCHOLOGICAL DISTRESS IN HEALTHY JAPANESE RESIDENTS: THE KOBE STUDY. Alcohol Alcohol 2017. [DOI: 10.1093/alcalc/agx074.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Uemura J, Kitano T, Shiromoto T, Kubo S, Wada Y, Yagita Y. Assessment of carotid plaque characteristics by contrast-enhanced ultrasound in the long-term after neck radiotherapy. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Yamauchi S, Zhong B, Kawamura K, Yang S, Kubo S, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes. BMC Cancer 2017; 17:622. [PMID: 28874135 PMCID: PMC5584036 DOI: 10.1186/s12885-017-3621-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Accepted: 08/28/2017] [Indexed: 12/26/2022] Open
Abstract
Background Replication-competent adenoviruses (Ad) produced cytotoxic effects on infected tumors and have been examined for the clinical applicability. A biomarkers to predict the cytotoxicity is valuable in a clinical setting. Methods We constructed type 5 Ad (Ad5) of which the expression of E1A gene was activated by a 5′ regulatory sequences of survivin, midkine or cyclooxygenase-2, which were highly expressed in human tumors. We also produced the same replication-competent Ad of which the fiber-knob region was replaced by that of Ad35 (AdF35). The cytotoxicity was examined by a colorimetric assay with human tumor cell lines, 4 kinds of pancreatic, 9 esophageal carcinoma and 5 mesothelioma. Ad infectivity and Ad-mediated gene expression were examined with replication-incompetent Ad5 and AdF35 which expressed the green fluorescence protein gene. Expression of cellular receptors for Ad5 and AdF35 was also examined with flow cytometry. A transcriptional activity of the regulatory sequences was investigated with a luciferase assay in the tumor cells. We then investigated a possible correlation between Ad-mediated cytotoxicity and the infectivity/gene expression, the transcriptional activity or the p53 genotype. Results We found that the cytotoxicity was greater with AdF35 than with Ad5 vectors, but was not correlated with the Ad infectivity/gene expression irrespective of the fiber-knob region or the E1A-activating transcriptional activity. In contrast, replication-competent Ad produced greater cytotoxicity in p53 mutated than in wild-type esophageal carcinoma cells, suggesting a possible association between the cytotoxicity and the p53 genotype. Conclusions Sensitivity to Ad-mediated cytotoxic activity was linked with the p53 genotype but was not lineally correlated with the infectivity/gene expression or the E1A expression. Electronic supplementary material The online version of this article (10.1186/s12885-017-3621-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Suguru Yamauchi
- Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.,Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Boya Zhong
- Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.,Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Kiyoko Kawamura
- Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan
| | - Shan Yang
- Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.,Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Shuji Kubo
- Department of Genetics, Hyogo College of Medicine, Nishinomiya, Japan
| | | | - Ikuo Sekine
- Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Yuji Tada
- Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Koichiro Tatsumi
- Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Hideaki Shimada
- Department of Surgery, School of Medicine, Toho University, Tokyo, Japan
| | - Kenzo Hiroshima
- Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan
| | - Masatoshi Tagawa
- Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan. .,Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
| |
Collapse
|
48
|
Kariya T, Minami R, Imai T, Kubo S, Shimozuma T, Takahashi H, Yoshimura Y, Ito S, Mutoh T, Ota M, Endo Y, Sakamoto K. Development of Mega-Watt Gyrotrons for Fusion Research. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11622] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Kariya
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - R. Minami
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - T. Imai
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - S. Kubo
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - H. Takahashi
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - S. Ito
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - M. Ota
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - Y. Endo
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency (JAEA), Naka, lharaki, 311-0193, Japan
| |
Collapse
|
49
|
Imai T, Ichimura M, Nakashima Y, Katanuma I, Yoshikawa M, Kariya T, Minami R, Miyata Y, Yamaguchi Y, Ikezoe R, Shimozuma T, Kubo S, Yoshimura Y, Takahashi H, Mutoh T, Sakamoto K, Mizuguchi M, Ota M, Ozawa H, Hosoi K, Yaguchi F, Yonenaga R, Imai Y, Murakani T, Yagi K, Nakamura T, Aoki1 H, Iizumi H, Ishii T, Kondou H, Takeda H, Ichioka N, Masaki S, Yokoyama T. Status and Plan of GAMMA 10 Tandem Mirror Program. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11563] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ichimura
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Nakashima
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - I. Katanuma
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Yoshikawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Kariya
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Minami
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Miyata
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Yamaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Ikezoe
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Shimozuma
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - S. Kubo
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - Y. Yoshimura
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - H. Takahashi
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - T. Mutoh
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - K. Sakamoto
- Japan Atomic Energy Research Institute(JAEA), Naka, Japan
| | - M. Mizuguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ota
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Ozawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Hosoi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - F. Yaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Yonenaga
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Murakani
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Yagi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | | - H. Aoki1
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Iizumi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Ishii
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Kondou
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Takeda
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - N. Ichioka
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - S. Masaki
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Yokoyama
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | |
Collapse
|
50
|
Kariya T, Minami R, Imai T, Shimozuma T, Kubo S, Yoshimura Y, Takahashi H, Ito S, Mutoh T, Nakabayashi H, Eguchi T, Numakura T, Endo Y, Mitsunaka Y, Sakamoto K. Development of 154 GHz 1 MW Gyrotron for ECRH of LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a16923] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Kariya
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - R. Minami
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Imai
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Shimozuma
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - H. Takahashi
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - S. Ito
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - H. Nakabayashi
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Eguchi
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Numakura
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - Y. Endo
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - Y. Mitsunaka
- Toshiba Electron Tubes & Devices Co., Ltd. (TETD), Otawara, Tochigi, 324-8550, Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency (JAEA), Naka, Ibaraki, 311-0193, Japan
| |
Collapse
|